Poliomyelitis
Conditions
Keywords
oral poliovirus vaccine, immunization, antibodies, poliovirus vaccines
Brief summary
This is an open-label randomized clinical trial that will compare immune responses among infants who receive either novel monovalent oral poliovirus vaccine type 2 (nOPV2) alone, bivalent oral poliovirus vaccine (bOPV) alone, or co-administered nOPV2 and bOPV.
Detailed description
It is expected that nOPV2 would replace mOPV2 for responding to type 2 outbreaks. Outbreak response for cVDPV2 also offers the opportunity to close immunity gaps to polioviruses types 1 and 3. Furthermore, GPEI might have to respond to two poliovirus outbreaks in the same geography. For either scenario, it would be important to get data on the immunogenicity of co-administered nOPV2 and bOPV, compared to either vaccine given alone. This clinical trial assesses and compares the immunogenicity of nOPV2 given with or without bOPV. Healthy infants 6 weeks of age will be enrolled in Dhaka, Bangladesh, and randomized to one of three study arms â Arm A: nOPV2 only, Arm B: nOPV2 and bOPV, or Arm C: bOPV only. Infants will be followed-up until 18 weeks of age through clinic and household visits. Blood specimens will be collected to test for immunological response. Stool specimens will be collected from infant vaccine recipients and one sibling household contact each to assess viral recombinants and nOPV2 household transmission.
Interventions
BIOLOGICALNovel monovalent oral poliovirus vaccine type 2 (nOPV2)
nOPV2 candidate 1 (S2/cre5/S15domV/rec1/hifi3) is a live-attenuated serotype-2 poliovirus that was derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells. To improve genetic stability, nucleotide sequence modifications were made in the major determinant for attenuation in the Sabin 5'-untranslated region. Additionally, two modifications in the polymerase 3D were made to further improve stability of the attenuation, and a key replication element from the 2C coding region was relocated to the 5'-untranslated region to inhibit recombination.
BIOLOGICALBivalent oral poliovirus vaccine (bOPV)
The live types 1 & 3 oral polio vaccine (bOPV) is a bivalent vaccine containing suspension of types 1 & 3 attenuated Polio viruses (Sabin strains).
Sponsors
Centers for Disease Control and Prevention
International Centre for Diarrhoeal Disease Research, Bangladesh
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
42 Days to 48 Days
Healthy volunteers
Yes
Inclusion criteria
* Healthy infants 6 weeks of age (range: 42-48 days). * Parents that consent for participation in the full length of the study. * Parents that can understand and comply with planned study procedures. * Infant has at least one sibling aged \<10 years living in the same household that is eligible for participation in the study.
Exclusion criteria
* Parents and infants who are unable to participate in the full length of the study (e.g., plan to move away from the study area during the study period). * A diagnosis or suspicion of immunodeficiency disorder either in the infant or in an immediate family member. * A diagnosis or suspicion of bleeding disorder that would contraindicate administration of bOPV or nOPV2 or collection of blood by venipuncture. * Acute diarrhoea, infection or illness at the time of enrolment (6 weeks of age) that would require infant's admission to a hospital. * Acute vomiting and intolerance to liquids within 24 hours before the enrolment visit (6 weeks of age). * Evidence of a chronic medical condition identified by a study medical officer during physical exam. * Receipt of any polio vaccine (OPV or IPV) before enrolment based upon documentation or parental recall. * Known allergy/sensitivity or reaction to polio vaccine, or its contents. * Infants from multiple births. Infants from multiple births will be excluded because the infant(s) who is/are not enrolled would likely receive OPV through routine immunization and transmit vaccine poliovirus to the enrolled infant. Even if all births from a multiple birth could be enrolled in the study, we will exclude multiple births as discontinuation of one may lead to discontinuation of multiple participants. * Infants from premature births (\<37 weeks of gestation).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vaccine response | Measured four weeks after administration of study vaccine(s). | Dichotomous (yes/no) variable defined as participants who are either seronegative (\<1:8 titers) at baseline who become seropositive (≥1:8) after vaccination (seroconversion) or participants who demonstrate a four-fold rise in titers after vaccination between two specimens, e.g. a change from 1:8 to 1:32, after adjusting for expected decay in maternal antibodies. Antibody titers at 6 weeks of age will be the starting point for the expected decline in maternal antibodies, assuming at half-life of 28 days. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Reciprocal antibody titers | Measured four weeks after administration of study vaccine(s). | Variable of the observed reciprocal antibody titer results. |
| Household transmission of nOPV2 | 1, 2, and 4 weeks after first vaccination with nOPV2 | Detection of type 2 OPV in stool of household contact |
| Viral recombinants | 2 and 4 weeks after first vaccination with study vaccine(s) | Detection and characterization of viral recombinants |
Countries
Bangladesh
Outcome results
None listed